July 2024 SCRI Release Copied
Trials and Trial Regimen Updates
Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAnalysts@scri.com.
New Builds Complete
| Study Number | Notes for New Build |
| 23084 | USOR 23084 Cohort 1 Arm 1 BT8009 D1,8,15 + Pembrolizumab Q21D
USOR 23084 Cohort 1 Arm 2 BT8009 D1,8 + Pembrolizumab Q21D USOR 23084 Cohort 1 Arm 3 Gemcitabine D1,8 + Carboplatin Q21D USOR 23084 Cohort 1 Arm 3 Gemcitabine D1,8 + Cisplatin Q21D USOR 23084 Cohort 1 Arm 3 Maintenance Avelumab D1,15 Q28D USOR 23084 Cohort 2 Arm 1 BT8009 D1,8,15 Q21D USOR 23084 Cohort 2 Arm 2 BT8009 D1,8 Q21D USOR 23084 Cohort 2 Arm 3 BT8009 + Pembrolizumab Q21D |
| 23340 | USOR 23340 Cohort 1 Livmoniplimab + Budigalimab + Pemetrexed + Carboplatin Q21D
USOR 23340 Cohort 1 Livmoniplimab + Budigalimab + Pemetrexed + Cisplatin Q21D USOR 23340 Cohort 1 Maintanence Livmoniplimab + Budigalimab + Pemetrexed Q21D USOR 23340 Cohort 2 Livmoniplimab + Budigalimab + Pemetrexed + Carboplatin Q21D USOR 23340 Cohort 2 Maintenance Livmoniplimab + Budigalimab + Pemetrexed Q21D USOR 23340 Cohort 3 Budigalimab + Pemetrexed + Carboplatin Q21D USOR 23340 Cohort 3 Budigalimab + Pemetrexed + Cisplatin Q21D USOR 23340 Cohort 3 Maintenance Budigalimab + Pemetrexed Q21D USOR 23340 Maintenance Pembrolizumab + Pemetrexed Q21D USOR 23340 Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 23340 Pembrolizumab + Pemetrexed + Cisplatin Q21D |
| 22095 | USOR 22095 DSP-5336 Q28D
USOR 22095 Part 1 DSP-5336 + Gilteritinib Q28D USOR 22095 Part 1 DSP-5336 + Venetoclax + Azacitidine D1-7 Q28D |
| 23284 | USOR 23284 ABBV-383 Q28D
USOR 23284 Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D USOR 23284 Carfilzomib D1,8,15 + Dexamethasone Q28D USOR 23284 Elotuzumab D1,8,15,22 fb D1 + Pomalidomide D1-21 + Dexamethasone D1,8,15,22 Q28D USOR 23284 Selinexor D1,8,15,22,29 + Bortezomib D1,8,15,22 + Dexamethasone Q35D |
23283 | USOR 23283 Rilvegostomig or Placebo + Capecitabine Q21D
USOR 23283 Rilvegostomig or Placebo + Gemcitabine D1,8 + Cisplatin D1,8 Q21D |
| 24049 | USOR 24049 HMPL-523 Part 1 Dose Escalation |
| 20345 | USOR 20345 Selinexor or Placebo + Ruxolitinib |
| 21271 | Administrative Amendment |
Additional Study Updates
| Study Number | Other Changes |
| 22220 | Administrative Amendment |
| 22187 | Updated Pharmacy Manual Administrative Amendment |
| 23195 | Updated Pharmacy Manual Administrative Amendment |
| 23009 | Administrative Amendment |
| 23261 | Updated Pharmacy Manual Administrative Amendment |
| 23244 | Updated Pharmacy Manual Administrative Amendment |
| 21457 | Administrative Amendment |
| 22232 | Administrative Amendment |
| 23016 | Administrative Amendment |
| 21533 | Administrative Amendment |
| 22022 | Administrative Amendment |
| 23203 | Administrative Amendment |